7-OH Experiences

Read firsthand accounts where people share them, in their own words. The public communities linked below are independent of this site; the fictional illustrations that follow are not contributors' stories.

Firsthand accounts

These links lead to public discussions, not verified testimonials. We do not verify posters' identities, product contents, medical histories, or reported outcomes. Some discussions contain distressing material or unsafe suggestions.

• r/quitting7oh on Reddit is a community focused on accounts of stopping 7-OH. Read contributors' original posts and the surrounding discussion at the source.
• r/quittingkratom on Reddit is a broader community about quitting kratom. Do not assume an account about leaf products describes the same exposure as concentrated 7-OH.

Neither community is operated by or affiliated with this site. No posts, usernames, screenshots, or personal medical histories are republished here.

What personal accounts cannot establish

A personal report does not verify what was in a product, establish causation, show how common an outcome is, or demonstrate that a treatment works. A helpful-sounding account is not a dosing or withdrawal plan. Do not follow medication or substitution instructions from a forum in place of professional care.

For research context, read Science and Evidence. If you are worried about your own use or someone else's, use Get Help and the clinician-conversation guide.

Fictional illustrations

The following scenarios are fictional composites, not real testimonials or verified case reports. They illustrate possible questions about concentrated 7-OH use without claiming how often any pattern occurs.

Composite 1: The product that became part of the schedule

An imagined person begins using a product before work. Later, they notice that planning the next serving occupies more attention than the original reason for taking it. They want to know whether discomfort between servings could be withdrawal.

The question for a clinician is not whether this proves a diagnosis. It is how to assess the product, symptoms, and pattern of use.

Composite 2: Relief and difficulty stopping

An imagined person hopes a product will help with pain. When they try to reduce use, they cannot tell whether their discomfort is the original pain, withdrawal, or something else. They bring the package and a record of use to an appointment.

This composite does not claim that a particular treatment resolved the problem. It illustrates why both the original concern and difficulty stopping belong in the conversation.

Composite 3: A botanical label with unanswered questions

An imagined person assumes a kratom-labeled tablet is comparable to leaf powder. On reviewing the package, they find the information insufficient to understand the exposure. They photograph the label and ask for professional guidance rather than inventing a conversion between products.

The useful question is what was actually taken, not whether the package looked familiar.

How these illustrations were built

We authored these scenarios to illustrate questions about product identity and difficulty stopping. FDA's clinician letter provides the risk context, including withdrawal concerns, but does not verify these invented people or events. FDA letter to health care professionals

No interviews, submitted stories, or individual forum posts were adapted into these fictional scenarios. The external community links above are a separate reading resource, not evidence that these imagined events happened. These composites cannot establish causation, prevalence, treatment effectiveness, or a typical timeline.

For evidence, read Science and Evidence. For support, see Get Help.